Cartesian Therapeutics
RNAC
63 hedge funds and large institutions have $107M invested in Cartesian Therapeutics in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 9 closing their positions.
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
19% more funds holding
Funds holding: 53 → 63 (+10)
0.21% less ownership
Funds ownership: 1.84% → 1.63% (-0.21%)
52% less capital invested
Capital invested by funds: $222M → $107M (-$115M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.24M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.94M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$1.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.46M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$17.4M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.5M |
| 3 |
PA
Perceptive Advisors
New York
|
-$7.71M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.73M |
| 5 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$548K |
RNAC Hedge Fund Activity: Q4 2017 in Review
63 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2017, worth a combined $107M — down 52% from $222M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RNAC positions and 9 closed out — a net gain of 10 holders — while 21 added to existing stakes and 14 trimmed.
The largest buyer was Millennium Management, adding an estimated $3.24M. The largest seller was Deerfield Management, exiting entirely with an estimated $17.4M sold.
- 63 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2017, up from 53 in Q3 2017.
- Funds reported $107M of Cartesian Therapeutics stock for Q4 2017, down 52% quarter-over-quarter.
- 19 funds opened new Cartesian Therapeutics positions in Q4 2017 and 9 closed out, a net change of +10 holders.
- The largest Cartesian Therapeutics buyer in Q4 2017 was Millennium Management, an estimated $3.24M added.
- The largest Cartesian Therapeutics seller in Q4 2017 was Deerfield Management, an estimated $17.4M sold.
Based on aggregated 13F filings for Q4 2017.